Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02154490 · ClinicalTrials.gov registry record
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 1,864
- Enrollment target
NCT02154490: Completed study, sponsored by SWOG Cancer Research Network.
NCT02154490 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 1,864 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02154490 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 1,864 participants
- Enrollment target
Study Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Primary Outcome
Percentage of participants that registered to a therapeutic sub-study out of those who received a sub-study assignment. To receive a sub-study assignment, enrolled participants must have submitted tissue, had biomarker results, and been matched to a therapeutic sub-study.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Durvalumab
- BIOLOGICAL Ipilimumab
- DRUG Erlotinib Hydrochloride
- DRUG FGFR Inhibitor AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,864 participants |
| Start Date | 2014-07-08 |
| Est. Completion | 2022-04-15 |
What the finished NCT02154490 record still lists
NCT02154490 is an observational study that tracks outcomes without assigning an intervention. Its 1,864 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02154490 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02154490 about?
NCT02154490 is a clinical study titled "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer". This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determ...
What is the current status of trial NCT02154490?
This trial is currently completed. The enrollment target is 1,864 participants. The study started on 2014-07-08. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT02154490?
The interventions under investigation include: Docetaxel (DRUG), Durvalumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Erlotinib Hydrochloride (DRUG), FGFR Inhibitor AZD4547 (DRUG).
Who is sponsoring clinical trial NCT02154490?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI